Categories
Business

Global Tumour-Induced Osteomalacia Market To Record Significant Rise In Revenue Share During Forecast Period : Fact.MR

A uncommon paraneoplastic condition of the bones called market or oncogenic osteomalacia consists of rickets or osteomalacia brought on by phosphaturic mesenchymal tumours. (PMT). Blood levels of phosphate, vitamin D-regulating hormone, and fibroblast growth factor 23 (FGF23) were shown to be higher in patients with tumour-induced osteomalacia. Research from Maastricht University Hospital indicates that 8% of cancer patients experience paraneoplastic syndrome.

Tumour-induced osteomalacia consists of the PMT which is induced by the wastage of renal phosphates due to the secretion of phosphatonin-like factors which hinders in phosphate uptake, also the excessive FGF23 halts the renal absorption of phosphate, which eventually deteriorate the bone health and strength. The Tumour-induced osteomalacia results in multiple biochemical malfunctioning such as elevated urine phosphate level (hyperphosphaturia) and low blood phosphate level (hypophosphatemia).

Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=5255

The global tumour-induced osteomalacia market is segmented into treatment, diagnosis, end-user and regions.

By treatment, the global tumour-induced osteomalacia market is further segmented into:

  • Drugs
    • Burosumab-twza
    • Cinarcalcet
  • Supplements
    • Calcium (Cinarcalcet,
    • Vitamin D (Calcitriol or Alphacalcidio)
    • Phosphorus
  • Surgery

By diagnosis, the global tumour-induced osteomalacia market is further segmented into:

  • Laboratories
    • Elevated blood Fibroblast growth factor 23 (FGF-23)
    • Serum calcium, PTH, vitamin D
    • Hyperphosphaturia (Secondary effects of the FDF-23)
    • Hypophosphatemia (Secondary effects of the FDF-23)
  • Bone Scan
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT Scan)
  • Differential Diagnosis
    • Vitamin D metabolism and deficiency
    • Osteoporosis
    • Renal Osteodystrophy
    • Others

By end-user, the global tumour-induced osteomalacia market is further segmented into:

  • Hospitals
  • Clinics

Tumour Induced Osteomalacia Market: Key Players

The key players of global tumour-induced osteomalacia market include Kyowa Kirin Co., Ltd., Taizhou Hisound Pharmaceutical Co., Ltd., Zhejiang Garden Biochemical High-tech Co., Ltd., Kingdomway Nutrition, Inc., Amgen Inc., Forgo Pharmaceuticals Pvt. Ltd., Abbott, Solvay, GE Healthcare, Siemens and others.

What Do You Get in a Fact.MR Study?

  • Factors affecting the overall development of the global Tumour-Induced Osteomalacia Market
  • Factor that might restrain the growth of the global market in the coming years of the forecast period.
  • What is present competitive scenario of the global Tumour-Induced Osteomalacia Market and its intricate details concerning potential business prospects of leading market players
  • Pricing strategies of several different market players in the global Tumour-Induced Osteomalacia Market

Why Choose Fact.MR?

  • Strong focus on delivering quality market reports
  • Round the clock customer service
  • Methodical and systematic approach while curating reports
  • Our aim is to help our clients meet their business targets

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583